8-Bromo-cAMP sodium salt NEW
Price | $41 | $58 | $78 |
Package | 5mg | 10mg | 25mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: 8-Bromo-cAMP sodium salt | CAS No.: 76939-46-3 |
Purity: 99.94% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | 8-Bromo-cAMP sodium salt |
Description | 8-Bromo-cAMP sodium salt (8-Br-Camp sodium salt) is a long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase(PKA), but resistant to degradation by cyclic AMP phosphodiesterase. |
In vitro | METHODS: Endothelial HUVECs were treated with 8-Bromo-cAMP sodium salt (100 μM) for 3 h. Cell migration was detected by Boyden Chamber assay. RESULTS: Increased cell migration was observed when conditioned media from MC3T3-E1 cells exposed to 8-Bromo-cAMP was supplemented with HUVECs. In contrast, conditioned medium from control untreated cells lacked this activity. [1] METHODS: The leukemia cell line AML193 was treated with 8-Bromo-cAMP sodium salt (1 mM) or IL-3 (500 ng/mL) for 1-15 min, and target protein expression levels were detected by Western Blot. RESULTS: In growth-arrested AML193 cells, the maximal effect of IL-3 on Erk1,2 phosphorylation was time-dependent and occurred within a time window of 5-15 min after the addition of growth factors. 8-Bromo-cAMP also induced Erk1,2 phosphorylation in these cells, with a maximal stimulation observable between 1-5 min. [2] |
In vivo | METHODS: To evaluate the effect of cAMP/PCA on angiogenesis and VM in CRC cells, 8-Bromo-cAMP sodium salt (60 mg/kg) was intraperitoneally injected into BALB/c mice bearing CT26 tumor tissues once a day for seven days. RESULTS: 8-Bromo-cAMP treatment significantly reduced the number of tumors. 8-Bromo-cAMP treatment inhibited angiogenesis and VM. 8-Bromo-cAMP acted through the cAMP/PKA-ERK pathway and EMT process in CRC. [3] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 80 mg/mL (186.01 mM), Heating is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 50 mg/mL (116.26 mM), Heating is recommended. |
Keywords | Protein kinase A | 8-Bromo-cAMP sodium | Inhibitor | 8BromocAMP sodium salt | PKA | 8-Br-Camp sodium | inhibit | 8 Bromo cAMP sodium salt |
Inhibitors Related | Daphnetin | Capivasertib | Ellagic acid | GSK180736A | Acefylline | Ro-3306 | Metadoxine | Staurosporine | Fasudil hydrochloride | JAK1/2/3 Inhibitor 1 |
Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Autophagy Compound Library | Anti-Viral Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Nucleotide Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/10g |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-09 | |
$55.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-12 | |
$0.00/1KG |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2023-02-01 | |
$0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-30 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY